Literature DB >> 24211634

Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis.

Amanda E Hoffman1, Michelle DeStefano, Carolyn Shoen, Krishnamoorthy Gopinath, Digby F Warner, Michael Cynamon, Robert P Doyle.   

Abstract

Tuberculosis (TB) causes up to 10 million incident cases worldwide per annum. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains are leading factors in the resurgence of TB cases and the need to produce new agents to combat such infection. Herein, we describe Co(II) and Cu(II) metal based complexes that feature the pyrophosphate ligand with notable selectivity and marked potency against Mycobacterium tuberculosis, including MDR strains. Such complexes are confirmed to be bacteriocidal and not affected by efflux inhibitors. Finally, while susceptibility to copper has recently been established for M. tuberculosis, the greater efficacy of cobalt observed herein is of considerable note and in line with the discovery of a copper metallothionein in M. tuberculosis.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bacteriocidal; Cobalt; Copper; INH; MDR-TB; MIC; MOTT; Mycobacteria other than TB; Pyrophosphate; TB; XDR-TB; extensively drug-resistant TB; isoniazid; minimum inhibitory concentration; multidrug-resistant TB; tuberculosis

Mesh:

Substances:

Year:  2013        PMID: 24211634     DOI: 10.1016/j.ejmech.2013.10.044

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

1.  Serum Concentrations of Trace Elements in Patients with Tuberculosis and Its Association with Treatment Outcome.

Authors:  Rihwa Choi; Hyoung-Tae Kim; Yaeji Lim; Min-Ji Kim; O Jung Kwon; Kyeongman Jeon; Hye Yun Park; Byeong-Ho Jeong; Won-Jung Koh; Soo-Youn Lee
Journal:  Nutrients       Date:  2015-07-21       Impact factor: 5.717

2.  Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis.

Authors:  Mariana R Sato; João A Oshiro Junior; Rachel Ta Machado; Paula C de Souza; Débora L Campos; Fernando R Pavan; Patricia B da Silva; Marlus Chorilli
Journal:  Drug Des Devel Ther       Date:  2017-03-20       Impact factor: 4.162

Review 3.  Recommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status Considerations.

Authors:  Rihwa Choi; Byeong Ho Jeong; Won Jung Koh; Soo Youn Lee
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

4.  Unprecedented in Vitro Antitubercular Activitiy of Manganese(II) Complexes Containing 1,10-Phenanthroline and Dicarboxylate Ligands: Increased Activity, Superior Selectivity, and Lower Toxicity in Comparison to Their Copper(II) Analogs.

Authors:  Pauraic McCarron; Malachy McCann; Michael Devereux; Kevin Kavanagh; Ciaran Skerry; Petros C Karakousis; Ana C Aor; Thaís P Mello; André L S Santos; Débora L Campos; Fernando R Pavan
Journal:  Front Microbiol       Date:  2018-07-02       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.